We’re about to get some key lung cancer data — and it could affect how hundreds of thousands of cancer patients are treated

This post was originally published on this site

On Monday, three big players in the growing field of cancer immunotherapy are sharing data that could change how we treat lung cancer. The three companies, Bristol-Myers Squibb, Merck, and Roche, are looking at how their immunotherapies, known as checkpoint inhibitors, can be used in combination – either with other immunotherapy or with chemotherapy to treat advanced non-small cell lung cancer.
More »